Animal model for mammary tumor growth in the bone microenvironment

Breast Cancer

Volumn 20, Issue 3, 2013, Pages 195-203

  Futakuchi, Mitsuru ^a   Singh, Rakesh K ^b  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Bone metastasis; Mammary tumor; Osteolysis; Transforming growth factor ; Tumor stromal interaction

Indexed keywords

CATHEPSIN G; CYCLOPENTHIAZIDE; OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA1; SOMATOMEDIN; SOMATOMEDIN RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2;

BONE METASTASIS; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER SURGERY; CANCER SURVIVAL; CELL PROLIFERATION; CELL STRUCTURE; DRUG TARGETING; ENZYME ACTIVATION; ENZYME REGULATION; GENE EXPRESSION; MOLECULAR DYNAMICS; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TUMOR INVASION; TUMOR MICROENVIRONMENT; ANIMAL; BONE TUMOR; DISEASE MODEL; EXPERIMENTAL MAMMARY NEOPLASM; FEMALE; HUMAN; MOUSE; PATHOLOGY; SECONDARY;

ANIMALS; BONE NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; TUMOR MICROENVIRONMENT;

EID: 84880037695     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-013-0439-5     Document Type: Review

References (66)

1. Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W, Sobue T. Cancer incidence and incidence rates in Japan in 2006: based on data from 15 population-based cancer registries in the monitoring of cancer incidence in Japan (MCIJ) project. Jpn J Clin Oncol. 2012;42:139-47. doi: 10.1093/jjco/hyr184.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29. doi: 10.3322/caac.20138.
3. Yi M, Liu P, Li X, Mittendorf EA, He J, Ren Y, Nayeemuddin K, Hunt KK. Comparative analysis of clinicopathologic features, treatment, and survival of Asian women with a breast cancer diagnosis residing in the United States. Cancer. 2012;118:4117-25. doi: 10.1002/cncr.27399.
4. Yip CH, Smith RA, Anderson BO, Miller AB, Thomas DB, Ang ES, Caffarella RS, Corbex M, Kreps GL, McTiernan A. Guideline implementation for breast healthcare in low- and middle-income countries: early detection resource allocation. Cancer. 2008;113:2244-56. doi: 10.1002/cncr.23842.
5. Jensen AO, Jacobsen JB, Norgaard M, Yong M, Fryzek JP, Sorensen HT. Incidence of bone metastases and skeletal-related events in breast cancer patients: a population-based cohort study in Denmark. BMC Cancer. 2011;11:29. doi: 10.1186/1471-2407-11-29.
6. Coleman RE. Future directions in the treatment and prevention of bone metastases. Am J clin oncol. 2002;25:S32-8. (Pubitemid 35453654)
7. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer. 1987;55:61-6. (Pubitemid 17234155)
8. Diel IJ, Solomayer EF, Bastert G. Treatment of metastatic bone disease in breast cancer: bisphosphonates. Clin Breast Cancer. 2000;1:43-51.
9. Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, Miller K, Sieber P, Karsh L, Damiao R, Tammela TL, Egerdie B, Van Poppel H, Chin J, Morote J, Gomez-Veiga F, Borkowski T, Ye Z, Kupic A, Dansey R, Goessl C. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2012;379:39-46. doi: 10.1016/S0140-6736(11)61226-9.
10. Barton MK. Denosumab an option for patients with bone metastasis from breast cancer. CA Cancer J Clin. 2011;61:135-6. doi: 10.3322/caac.20116.
11. Charhon SA, Chapuy MC, Delvin EE, Valentin-Opran A, Edouard CM, Meunier PJ. Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma special reference to osteomalacia. Cancer. 1983;51:918-24. (Pubitemid 13143171)
12. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2:584-93. doi: 10.1038/nrc867nrc867. (Pubitemid 37328925)
13. Leibbrandt A, Penninger JM. RANKL/RANK as key factors for osteoclast development and bone loss in arthropathies. Adv Exp Med Biol. 2009;649:100-13.
14. Delaisse JM, Andersen TL, Engsig MT, Henriksen K, Troen T, Blavier L. Matrix metalloproteinases (MMP) and cathepsin K contribute differently to osteoclastic activities. Microsc Res Tech. 2003;61:504-13. doi: 10.1002/jemt.10374. (Pubitemid 36890583)
15. Guo B, Villeneuve DJ, Hembruff SL, Kirwan AF, Blais DE, Bonin M, Parissenti AM. Cross-resistance studies of isogenic drug-resistant breast tumor cell lines support recent clinical evidence suggesting that sensitivity to paclitaxel may be strongly compromised by prior doxorubicin exposure. Breast Cancer Res Treat. 2004;85:31-51. doi: 10.1023/B:BREA.0000021046.29834.12. (Pubitemid 38437981)
16. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, Guise TA, Massague J. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 2003;3:537-49. (Pubitemid 36808649)
17. Kuperwasser C, Dessain S, Bierbaum BE, Garnet D, Sperandio K, Gauvin GP, Naber SP, Weinberg RA, Rosenblatt M. A mouse model of human breast cancer metastasis to human bone. Cancer Res. 2005;65:6130-8. doi: 10.1158/0008-5472. can-04-1408. (Pubitemid 40994398)
18. Murphy BO, Joshi S, Kessinger A, Reed E, Sharp JG. A murine model of bone marrow micrometastasis in breast cancer. Clin Exp Metastasis. 2002;19:561-9. (Pubitemid 36001998)
19. Nemeth JA, Harb JF, Barroso U Jr, He Z, Grignon DJ, Cher ML. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone. Cancer Res. 1999;59:1987-93. (Pubitemid 29186176)
20. Reddi AH, Roodman D, Freeman C, Mohla S. Mechanisms of tumor metastasis to the bone: challenges and opportunities. J Bone Miner Res. 2003;18:190-4. doi: 10.1359/jbmr.2003.18.2.190. (Pubitemid 36125910)
21. Shtivelman E, Namikawa R. Species-specific metastasis of human tumor cells in the severe combined immunodeficiency mouse engrafted with human tissue. Proc Natl Acad Sci USA. 1995;92:4661-5.
22. Yoneda T, Hiraga T. Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun. 2005;328:679-87. doi: 10.1016/j.bbrc.2004.11.070. (Pubitemid 40208305)
23. Hiraga T, Ueda A, Tamura D, Hata K, Ikeda F, Williams PJ, Yoneda T. Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer. Int J cancer. 2003;106:973-9. doi: 10.1002/ijc.11330. (Pubitemid 37071680)
24. Iguchi H, Tanaka S, Ozawa Y, Kashiwakuma T, Kimura T, Hiraga T, Ozawa H, Kono A. An experimental model of bone metastasis by human lung cancer cells: the role of parathyroid hormone-related protein in bone metastasis. Cancer Res. 1996;56:4040-3. (Pubitemid 26284757)
25. Zhu L, Loo WT, Chow LW. Circulating tumor cells in patients with breast cancer: possible predictor of micro-metastasis in bone marrow but not in sentinel lymph nodes. Biomed Pharmacother 2005; 59 Suppl 2: S355-8.
26. Abramson VG, Mayer IA. Clinical utility of serum tumor markers and circulating tumor cell assays in the treatment of breast cancer. Curr Treat Options Oncol. 2011;12:403-11. doi: 10.1007/s11864-011-0164-2.
27. Reyal F, Valet F, de Cremoux P, Mathiot C, Decraene C, Asselain B, Brain E, Delaloge S, Giacchetti S, Marty M, Pierga JY, Bidard FC. Circulating tumor cell detection and transcriptomic profiles in early breast cancer patients. Ann Oncol Off J European Soc Med Oncol/ESMO. 2011;22:1458-9. doi: 10.1093/annonc/mdr144.
28. Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 1989;8:98-101.
29. Patel SA, Dave MA, Murthy RG, Helmy KY, Rameshwar P. Metastatic breast cancer cells in the bone marrow microenvironment: novel insights into oncoprotection. Oncol Rev. 2011;5:93-102. doi: 10.1007/s12156-010-0071-y.
30. Siclari VA, Guise TA, Chirgwin JM. Molecular interactions between breast cancer cells and the bone microenvironment drive skeletal metastases. Cancer Metastasis Rev. 2006;25:621-33. doi: 10.1007/s10555-006-9023-1. (Pubitemid 46075000)
31. Luis-Ravelo D, Anton I, Vicent S, Hernandez I, Valencia K, Zandueta C, Martinez-Canarias S, Gurpide A, Lecanda F. Tumor-stromal interactions of the bone microenvironment: in vitro findings and potential in vivo relevance in metastatic lung cancer models. Clin Exp Metastasis. 2011;28:779-91. doi: 10.1007/s10585-011-9409-5.
32. Sosnoski DM, Krishnan V, Kraemer WJ, Dunn-Lewis C, Mastro AM. Changes in cytokines of the bone microenvironment during breast cancer metastasis. Int J Breast cancer. 2012;2012:160265. doi: 10.1155/2012/160265.
33. Lynch CC, Hikosaka A, Acuff HB, Martin MD, Kawai N, Singh RK, Vargo-Gogola TC, Begtrup JL, Peterson TE, Fingleton B, Shirai T, Matrisian LM, Futakuchi M. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell. 2005;7:485-96. (Pubitemid 40719131)
34. Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 1992;52:1399-405.
35. Huang X, Wong MK, Yi H, Watkins S, Laird AD, Wolf SF, Gorelik E. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein. Cancer Res. 2002;62:5727-35. (Pubitemid 35204728)
36. Sloan EK, Stanley KL, Anderson RL. Caveolin-1 inhibits breast cancer growth and metastasis. Oncogene. 2004;23:7893-7. doi: 10.1038/sj.onc.1208062. (Pubitemid 39457039)
37. Lelekakis M, Moseley JM, Martin TJ, Hards D, Williams E, Ho P, Lowen D, Javni J, Miller FR, Slavin J, Anderson RL. A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis. 1999;17:163-70. (Pubitemid 29335443)
38. Heppner GH, Miller FR, Shekhar PM. Nontransgenic models of breast cancer. Breast cancer Res BCR. 2000;2:331-4. (Pubitemid 32223615)
39. Kakonen SM, Mundy GR. Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer. 2003;97:834-9. doi: 10.1002/cncr.11132. (Pubitemid 36125820)
40. Hiraga T, Myoui A, Choi ME, Yoshikawa H, Yoneda T. Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer. Cancer Res. 2006;66:2067-73. doi: 10.1158/0008-5472.can-05-2012.
41. Guise TA, Mohammad KS, Clines G, Stebbins EG, Wong DH, Higgins LS, Vessella R, Corey E, Padalecki S, Suva L, Chirgwin JM. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res. 2006;12:6213s-6s. doi: 10.1158/1078-0432.ccr-06-1007. (Pubitemid 44703792)
42. Kakonen SM, Selander KS, Chirgwin JM, Yin JJ, Burns S, Rankin WA, Grubbs BG, Dallas M, Cui Y, Guise TA. Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. J Biol Chem. 2002;277:24571-8. doi: 10.1074/jbc.M202561200. (Pubitemid 34951984)
43. Bierie B, Moses HL. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer. 2006;6:506-20. doi: 10.1038/nrc1926. (Pubitemid 43980540)
44. Oft M, Heider KH, Beug H. TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol CB. 1998;8:1243-52. (Pubitemid 28540052)
45. Oft M, Peli J, Rudaz C, Schwarz H, Beug H, Reichmann E. TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev. 1996;10:2462-77. (Pubitemid 26341881)
46. Bierie B, Stover DG, Abel TW, Chytil A, Gorska AE, Aakre M, Forrester E, Yang L, Wagner KU, Moses HL. Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment. Cancer Res. 2008;68:1809-19. doi: 10.1158/0008-5472.can-07-5597. (Pubitemid 351416566)
47. Massague J. TGF-beta signal transduction. Annu Rev Biochem. 1998;67:753-91. doi: 10.1146/annurev.biochem.67.1.753. (Pubitemid 28411144)
48. Massague J, Gomis RR. The logic of TGFbeta signaling. FEBS Lett. 2006;580:2811-20. doi: 10.1016/j.febslet.2006.04.033. (Pubitemid 43729163)
49. Futakuchi M, Nannuru KC, Varney ML, Sadanandam A, Nakao K, Asai K, Shirai T, Sato SY, Singh RK. Transforming growth factor-beta signaling at the tumor-bone interface promotes mammary tumor growth and osteoclast activation. Cancer Sci. 2009;100:71-81. doi: 10.1111/j.1349-7006.2008.01012.x.
50. Warwick-Davies J, Lowrie DB, Cole PJ. Selective deactivation of human monocyte functions by TGF-beta. J Immun. 1995;155:3186-93.
51. Fuller K, Lean JM, Bayley KE, Wani MR, Chambers TJ. A role for TGFbeta(1) in osteoclast differentiation and survival. J Cell Sci. 2000;113(Pt 13):2445-53. (Pubitemid 30599346)
52. Sells Galvin RJ, Gatlin CL, Horn JW, Fuson TR. TGF-beta enhances osteoclast differentiation in hematopoietic cell cultures stimulated with RANKL and M-CSF. Biochem Biophys Res Commun. 1999;265:233-9. doi: 10.1006/bbrc.1999. 1632.
53. Fox SW, Haque SJ, Lovibond AC, Chambers TJ. The possible role of TGF-beta-induced suppressors of cytokine signaling expression in osteoclast/macrophage lineage commitment in vitro. J Immunol (Baltimore, Md.: 1950) 2003; 170: 3679-3687. (Pubitemid 36359238)
54. Guise TA, Chirgwin JM. Transforming growth factor-beta in osteolytic breast cancer bone metastases. Clin Orthop Relat Res 2003; S32-38. doi: 10.1097/01.blo.0000093055.96273.69. (Pubitemid 37323317)
55. Bandyopadhyay A, Agyin JK, Wang L, Tang Y, Lei X, Story BM, Cornell JE, Pollock BH, Mundy GR, Sun LZ. Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor. Cancer Res. 2006;66:6714-21. doi: 10.1158/0008-5472.can-05-3565. (Pubitemid 44085629)
56. Sato S, Futakuchi M, Ogawa K, Asamoto M, Nakao K, Asai K, Shirai T. Transforming growth factor beta derived from bone matrix promotes cell proliferation of prostate cancer and osteoclast activation-associated osteolysis in the bone microenvironment. Cancer Sci. 2008;99:316-23. doi: 10.1111/j.1349-7006.2007.00690.x. (Pubitemid 351228486)
57. Ohshiba T, Miyaura C, Inada M, Ito A. Role of RANKL-induced osteoclast formation and MMP-dependent matrix degradation in bone destruction by breast cancer metastasis. Br J Cancer. 2003;88:1318-26. doi: 10.1038/sj.bjc.6600858. (Pubitemid 36606352)
58. Jimi E, Aoki K, Saito H, D'Acquisto F, May MJ, Nakamura I, Sudo T, Kojima T, Okamoto F, Fukushima H, Okabe K, Ohya K, Ghosh S. Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat Med. 2004;10:617-24. doi: 10.1038/nm1054. (Pubitemid 38796853)
59. Wilson TJ, Nannuru KC, Futakuchi M, Sadanandam A, Singh RK. Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-kappaB ligand. Cancer Res. 2008;68:5803-11. doi: 10.1158/0008-5472.CAN-07-5889.
60. Selak MA, Chignard M, Smith JB. Cathepsin G is a strong platelet agonist released by neutrophils. Biochem J. 1988;251:293-9.
61. Fata JE, Kong YY, Li J, Sasaki T, Irie-Sasaki J, Moorehead RA, Elliott R, Scully S, Voura EB, Lacey DL, Boyle WJ, Khokha R, Penninger JM. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell. 2000;103:41-50.
62. Cao Y, Bonizzi G, Seagroves TN, Greten FR, Johnson R, Schmidt EV, Karin M. IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. Cell. 2001;107:763-75. (Pubitemid 34033669)
63. Cao Y, Luo JL, Karin M. IkappaB kinase alpha kinase activity is required for self-renewal of ErbB2/Her2-transformed mammary tumor-initiating cells. Proc Natl Acad Sci USA. 2007;104:15852-7. doi: 10.1073/pnas.0706728104. (Pubitemid 350035388)
64. Luo JL, Tan W, Ricono JM, Korchynskyi O, Zhang M, Gonias SL, Cheresh DA, Karin M. Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature. 2007;446:690-4. doi: 10.1038/nature05656. (Pubitemid 46606879)
65. Tan W, Zhang W, Strasner A, Grivennikov S, Cheng JQ, Hoffman RM, Karin M. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature. 2011;470:548-53. doi: 10.1038/nature09707.
66. Sadanandam A, Futakuchi M, Lyssiotis CA, Gibb WJ, Singh RK. A cross-species analysis of a mouse model of breast cancer-specific osteolysis and human bone metastases using gene expression profiling. BMC Cancer. 2011;11:304. doi: 10.1186/1471-2407-11-304.